Profit From These Special Situationshttp://www.fool.com/investing/general/2011/12/30/profit-from-these-special-situations.aspx Rich Duprey
December 30, 2011
In his book You Can Be a Stock Market Genius, author and investor Joel Greenblatt highlighted the opportunity hidden in mergers and acquisitions, spinoffs, and restructurings. Some deals are so complex that the true value of a stock won't be unlocked until well after the fact, giving savvy investors a chance to get in early and grab hold of shares at a discount. Huge profits are possible, and he achieved 50% annualized returns for a decade investing in them.
We'll look at the latest announcements presenting an opportunity for profit and pair that with the views of the 180,000 members of Motley Fool CAPS to see what they think of the businesses involved. If the best and brightest in the investment community like these stocks, it may be worth your time to dive in further.
But not every deal is worth your money. It takes diving into the filings to understand the nuances, so don't use the stocks below as a buy list -- more due diligence is needed on your part.
Source: Motley Fool CAPS.
Again, this is just a starting point for further research. Do your homework before committing real money to these special situations.
Isn't that special?
Investors would receive shares of the new company in a tax-free distribution. This follows Abbott Labs' decision in October to spin off its own pharmaceuticals business and Pfizer's (NYSE: PFE ) wanting to rid itself of its animal health and nutrition division.
While analysts generally liked the move for Covidien, itself a spinoff from Tyco (NYSE: TYC ) , as it frees it from a lower-margin business, there are questions about how well that operation will be received. Covidien tried to sell the division earlier this year and didn't find a buyer, meaning such disdain may create opportunity.
The new company would have Exalgo and Pennsaid, a topical anti-inflammatory medication, and is already among the top 10 generic pharmaceuticals manufacturers in the U.S. It also supplies generators used to produce technetium-99m, a medical isotope widely used to diagnose diseases.
Highly rated CAPS All-Star TMFDeej also likes the move for Covidien, which he's now rated to outperform the market on CAPS. Let us know in the comments section below or on the Covidien CAPS page whether you'd consider buying into the spinoff too, and then add it to your watchlist to see how successful it is.
At the REIT moment
The General, second in size to Simon Property Group, owns some 167 malls. Its purchase of Rouse back in 2004 and the heavy debt load it brought on likely played a big role in ultimately leading the mall operator to declare bankruptcy. Though it expects to close the transaction by Jan. 12, if the deal's not done by then, it will pay a special cash dividend.
Rouse is expected to have a fairly significant $1.16 billion debt load when it's spun off. With existing shareholders ending up with exceedingly small ownership stakes in the new company, they may just sell them off to get rid of them, depressing its price. After the distribution, though, Brookfield Asset Management, which is providing a $100 million revolving credit facility to Rouse, has agreed to buy up any remaining shares not exercised at the $15 offering price of a subsequent offering.